- Home
- PMCB vs BCDA Comparison
PMCB vs BCDA Comparison
Compare PMCB & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMCB
- BCDA
- Stock Information
- Founded
- PMCB 1996
- BCDA N/A
- Country
- PMCB United States
- BCDA United States
- Employees
- PMCB N/A
- BCDA N/A
- Industry
- PMCB Biotechnology: Biological Products (No Diagnostic Substances)
- BCDA Biotechnology: Pharmaceutical Preparations
- Sector
- PMCB Health Care
- BCDA Health Care
- Exchange
- PMCB Nasdaq
- BCDA Nasdaq
- Market Cap
- PMCB 11.4M
- BCDA 9.4M
- IPO Year
- PMCB N/A
- BCDA N/A
- Fundamental
- Price
- PMCB $1.06
- BCDA $2.87
- Analyst Decision
- PMCB
- BCDA Strong Buy
- Analyst Count
- PMCB 0
- BCDA 1
- Target Price
- PMCB N/A
- BCDA $25.00
- AVG Volume (30 Days)
- PMCB 11.3K
- BCDA 88.9K
- Earning Date
- PMCB 03-17-2025
- BCDA 05-20-2025
- Dividend Yield
- PMCB N/A
- BCDA N/A
- EPS Growth
- PMCB N/A
- BCDA N/A
- EPS
- PMCB 1.29
- BCDA N/A
- Revenue
- PMCB N/A
- BCDA $58,000.00
- Revenue This Year
- PMCB N/A
- BCDA N/A
- Revenue Next Year
- PMCB N/A
- BCDA N/A
- P/E Ratio
- PMCB $0.85
- BCDA N/A
- Revenue Growth
- PMCB N/A
- BCDA N/A
- 52 Week Low
- PMCB $1.03
- BCDA $1.63
- 52 Week High
- PMCB $2.42
- BCDA $6.15
- Technical
- Relative Strength Index (RSI)
- PMCB 36.21
- BCDA 58.73
- Support Level
- PMCB $1.08
- BCDA $2.40
- Resistance Level
- PMCB $1.39
- BCDA $2.87
- Average True Range (ATR)
- PMCB 0.10
- BCDA 0.27
- MACD
- PMCB 0.00
- BCDA 0.06
- Stochastic Oscillator
- PMCB 0.00
- BCDA 71.18
About PMCB PharmaCyte Biotech Inc.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).